HM2002 offers advantages due to its composition of circular RNAs, which provide improved stability and low immunogenicity.

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

a VEGF 'trap' compound that targets two forms of the protein – VEGF-C and VEGF-D – designed to complement the effects of current drugs like Eylea that target VEGF-A. It is actually running two ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

The three major Hong Kong stock indices weakened collectively. By the close, the Hang Seng Index fell 0.08% to 24,162.87, the Tech Index dropped 0.76% to 5,392.19, and the HSCEI declined 0.15% to ...

Sozinibercept is a VEGF ‘trap’ compound that targets two forms of the protein – VEGF-C and VEGF-D – designed to complement the effects of Eylea and Lucentis on VEGF-A. If the phase 2 ...

Smoking cannabis and consuming THC edibles are both linked to impaired blood vessel dilation, possibly through separate ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around ...

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.